MDA-MB-231 cells, a human breast cancer line, has been used to elucidate UBL3 as a post-translational modification factor (Ageta et al., 2018), were treated with doxycycline (DOX) for 1.5 h. This evidence concerns the gene UBL3 and breast cancer.